Kian Immune Cell Co. hosted a lively scientific discussion that brought together researchers, students, and colleagues for an exchange the company describes as genuine scientific thinking in action.
Zohreh Mirlavasani shared insights on dendritic cell (DC) vaccines and explored how artificial intelligence could improve their development and therapeutic efficacy. Students and colleagues from the Royan Cancer Stem Cell Group engaged actively throughout the session, raising thoughtful questions and driving a wide-ranging scientific brainstorm.
The discussion converged on one of the most compelling questions in cancer immunotherapy today: which holds greater potential for treating cancer — mRNA vaccines or DC vaccines? No simple answer emerged, and the conversation reflected the depth and fast-evolving nature of the field. Kian Immune Cell Co. looks forward to continuing this dialogue and invites the broader scientific community to share their perspectives.
